Cardiovascular and Thoracic Surgery Department, St. Luc's Hospital, Catholic University of Louvain, Brussels, Belgium.
Cardiac Surgery Department, University Hospital Munster, Munster, Germany.
Transplantation. 2018 Jun;102(6):e288-e294. doi: 10.1097/TP.0000000000002105.
Outcomes of continuous flow left ventricular assist devices (CF-LVADs) as bridge to transplant have significantly improved. The question has arisen whether patients on CF-LVADs have an increased risk of death on the waiting list as to justify a priority allocation (status 1). The aim of this study was to compare the survival after implantation of CF-LVADs with the survival on the waiting list for patients initially listed in United Network for Organ Sharing (UNOS) status 2.
All patients 18 years or older listed for heart transplantation (HT) in the United States between 2011 and 2013 in UNOS status 2 with no mechanical circulatory support at time of listing were analyzed. Patients were divided into 2 groups, depending on whether they received a new CF-LVAD while listed (CF-LVAD group) or not (NO-LVAD) and were further matched on their propensity score (PS) in a 1:2 ratio.
Two hundred eighty-seven CF-LVAD patients were matched to 574 NO-LVAD patients. Survival after CF-LVAD was significantly lower at 24 months compared with waiting list (75.4 ± 4.4% vs 91.2 ± 8.9%, P < 0.0001). Further, survival was not significantly different between the 2 groups at 24 months after transplantation (81.3 ± 5.9% vs 86.7 ± 3.3%, P = 0.3).
Survival of patients listed in UNOS status 2 who receive a CF-LVAD while listed is significantly lower compared to patients who do not receive mechanical support on the waiting list. The current priority in the allocation system given to patients on CF-LVAD seems justified. Further posttransplant survival is not negatively influenced by previous CF-LVAD implantation.
连续流动左心室辅助装置(CF-LVAD)作为移植桥的结果显著改善。因此,出现了一个问题,即接受 CF-LVAD 治疗的患者在等待名单上的死亡风险是否增加,以至于需要优先分配(状态 1)。本研究旨在比较 CF-LVAD 植入后患者的存活率与最初在联合器官共享网络(UNOS)状态 2 中列出的患者在等待名单上的存活率。
分析了 2011 年至 2013 年期间在美国 UNOS 状态 2 中列出的年龄在 18 岁或以上的所有接受心脏移植(HT)的患者,这些患者在列入名单时没有机械循环支持。患者分为 2 组,一组是在列入名单时接受新的 CF-LVAD(CF-LVAD 组),另一组没有接受(NO-LVAD),并根据倾向评分(PS)以 1:2 的比例进行进一步匹配。
287 例 CF-LVAD 患者与 574 例 NO-LVAD 患者相匹配。与等待名单相比,CF-LVAD 治疗后 24 个月的生存率明显较低(75.4 ± 4.4%比 91.2 ± 8.9%,P < 0.0001)。此外,移植后 24 个月时,两组之间的生存率无显著差异(81.3 ± 5.9%比 86.7 ± 3.3%,P = 0.3)。
在 UNOS 状态 2 中列出的患者中,接受 CF-LVAD 的患者的生存率明显低于未在等待名单上接受机械支持的患者。目前,在分配系统中给予 CF-LVAD 患者的优先权似乎是合理的。进一步的移植后生存并未因先前的 CF-LVAD 植入而受到负面影响。